Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study - Archive ouverte HAL
Article Dans Une Revue Liver International Année : 2022

Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study

Christophe Duvoux
Jérôme Dumortier
Yvon Calmus
Jean Gugenheim
Ephrem Salamé
François Durand
Yasmina Benkhatar
  • Fonction : Auteur
François Derquenne
  • Fonction : Auteur
Filomena Conti

Résumé

Background and Aims: To report 5-year outcomes of the CERTITUDE study. Methods: An observational study in patients with liver transplantation (LTx) compared the long-term impact of immunosuppression (with/without a calcineurin inhibitor) on renal function, cancers, major cardiovascular events (MACEs) and other safety parameters. All patients completing the 6-month SIMCER study were recruited and analysed according to treatment received at randomization and actual treatment received during the follow-up.

Dates et versions

hal-04183810 , version 1 (21-08-2023)

Licence

Identifiants

Citer

Faouzi Saliba, Christophe Duvoux, Sébastien Dharancy, Jérôme Dumortier, Yvon Calmus, et al.. Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study. Liver International, 2022, 42 (11), pp.2513-2523. ⟨10.1111/liv.15396⟩. ⟨hal-04183810⟩
22 Consultations
0 Téléchargements

Altmetric

Partager

More